BIOL vs. SONX, SDCCQ, BMRA, SDC, XRAY, NVST, ZIMV, EKSO, GDTC, and INDP
Should you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include Sonendo (SONX), SmileDirectClub (SDCCQ), Biomerica (BMRA), SmileDirectClub (SDC), DENTSPLY SIRONA (XRAY), Envista (NVST), ZimVie (ZIMV), Ekso Bionics (EKSO), CytoMed Therapeutics (GDTC), and Indaptus Therapeutics (INDP). These companies are all part of the "medical" sector.
Sonendo (NYSE:SONX) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.
Sonendo currently has a consensus price target of $1.88, indicating a potential upside of 2,085.31%. BIOLASE has a consensus price target of $0.40, indicating a potential upside of 134.19%. Given BIOLASE's higher possible upside, analysts plainly believe Sonendo is more favorable than BIOLASE.
In the previous week, BIOLASE had 3 more articles in the media than Sonendo. MarketBeat recorded 3 mentions for BIOLASE and 0 mentions for Sonendo. Sonendo's average media sentiment score of 0.22 beat BIOLASE's score of 0.00 indicating that BIOLASE is being referred to more favorably in the news media.
28.7% of Sonendo shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 6.4% of Sonendo shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Sonendo has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, BIOLASE has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
BIOLASE received 278 more outperform votes than Sonendo when rated by MarketBeat users. Likewise, 55.05% of users gave BIOLASE an outperform vote while only 40.74% of users gave Sonendo an outperform vote.
BIOLASE has higher revenue and earnings than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.
BIOLASE has a net margin of -43.56% compared to BIOLASE's net margin of -130.16%. BIOLASE's return on equity of -150.01% beat Sonendo's return on equity.
Summary
BIOLASE beats Sonendo on 10 of the 17 factors compared between the two stocks.
Get BIOLASE News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
